Therapy with oral antidiabetic drugs: applied pharmacogenetics
- 1 January 2011
- journal article
- Published by SAGE Publications in British Journal of Diabetes
- Vol. 11 (1) , 10-16
Abstract
Pharmacogenetics focuses on the relationship between individual gene variants and variable drug effects. The present brief review addresses the importance of pharmacogenetic factors for the efficacy and adverse effects of oral antidiabetic drugs in the therapy of type 2 diabetes mellitus. In particular, genetic polymorphisms of cytochrome P450 drug metabolizing enzymes, peroxisome proliferator-activated receptor- γ gene, TCF7L2 gene regulating insulin resistance and secretion and organic cation transporters or organic anion transporting polypeptides modify the individual response to drugs such as metformin, thiazolidinediones, sulphonylureas, meglitinides, and DPP4 inhibitors. However, apart from a complex variety of individual factors, genetic heterogeneity makes assessing the role of genetic factors in diabetes therapy for a single individual highly challenging. Continuing advances in pharmacogenetics will uncover further genetic variants that modify responses to diabetes medications and may offer targeted pharmacotherapy to the patient.Keywords
This publication has 36 references indexed in Scilit:
- No significant effect ofSLCO1B1polymorphism on the pharmacokinetics of rosiglitazone and pioglitazoneBritish Journal of Clinical Pharmacology, 2007
- Variation in TCF7L2 Influences Therapeutic Response to SulfonylureasDiabetes, 2007
- Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphismsDiabetologia, 2007
- Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoproteinThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin actionJournal of Clinical Investigation, 2007
- Drug-Drug and Food-Drug Pharmacokinetic Interactions with New Insulinotropic Agents Repaglinide and NateglinideClinical Pharmacokinetics, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy VolunteersClinical Pharmacokinetics, 2004
- Analysis of the Relationship Between the Pro12Ala Variant in the PPAR-γ2 Gene and the Response Rate to Therapy With Pioglitazone in Patients With Type 2 DiabetesDiabetes Care, 2003
- Clinical Pharmacokinetics of MetforminClinical Pharmacokinetics, 1996